[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Pages 8981-8982]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3907]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Treatment of Glaucoma by 
Administration of Adenosine A3 Antagonists

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in U.S. 
Provisional Patent Application 60/010,737, entitled ``Dihydropyridine, 
pyridine-, benzopyran one-, and triazoloquinazoline derivatives, their 
preparation and use as adenosine receptor antagonists,'' filed January 
29, 1996 [HHS Ref. No. E-225-1995/0-US-1], U.S. Provisional Patent 
Application 60/021,191, entitled ``Dihydropyridine, pyridine-, 
benzopyran one-, and triazoloquinazoline derivatives, their preparation 
and use as adenosine receptor antagonists,'' filed July 3, 1996 [HHS 
Ref. No. E-225-1995/1-US-1], PCT Application PCT/US97/01252, entitled 
``Dihydropyridine, pyridine-, benzopyran one-, and triazoloquinazoline 
derivatives, their preparation and use as adenosine receptor 
antagonists,'' filed January 29, 1997 [HHS Ref. No. E-225-1995/2-PCT-
1], U.S. Patent 6,066,642, entitled ``Dihydropyridine, pyridine-, 
benzopyran one-, and triazoloquinazoline derivatives, their preparation 
and use as adenosine receptor antagonists,'' issued May 23, 2000 [HHS 
Ref. No. E-225-1995/2-US-08], Australian Patent 709190, issued December 
9, 1999 [HHS Ref. No. E-225-1995/2-AU-04], European Patent Application 
No. 97905627.2, filed January 29, 1997 [HHS Ref. No. E-225-1995/2-EP-
05], Hong Kong Application No. 99102653.6, filed January 29, 1997 [HHS 
Ref. No. E-225-1995/2-HK-06], Japanese Patent Application No. 527065/
1997, filed January 29, 1997 [HHS Ref. No. E-225-1995/2-JP-07], 
Australian Patent 755525, issued March 27, 2003 [HHS Ref. No. E-225-
1995/2-AU-02], and Canadian Patent 2244774, issued October 17, 2006 
[HHS Ref. No. E-225-1995/2-CA-03], U.S. Provisional Patent Application 
60/092,292, entitled ``A3 Adenosine Receptor Antagonists,'' filed July 
10, 1998 [HHS Ref. No. E-096-1998/0-US-1], PCT Application PCT/US99/
15562, entitled''A3 Adenosine Receptor Antagonists,'' filed July 2, 
1999 [HHS Ref. No. E-096-1998/0-PCT-2], U.S. Patent 6,376,521, entitled 
``A3 Adenosine Receptor Antagonists,'' issued April 23, 2003, [HHS Ref. 
No. E-096-1998/0-US-04], and Canadian Patent Application No. 2336967, 
filed July 2, 1999 [HHS Ref. No. E-096-1998/0-CA-03], U.S. Provisional 
Patent Application 61/085,588, entitled ``Truncated Methanacarba 
Adenosine Derivatives as A3 Antagonists,'' filed August 1, 2008 [HHS 
Ref. No. E-285-2008/0-US-1], PCT Application PCT/US2009/52439, entitled 
``Truncated Methanacarba Adenosine Derivatives as A3 Antagonists,'' 
filed July 31, 2009 [HHS Ref. No. E-285-2008/0-PCT-2], and Korean 
International Application No. PCT/KR2007/001131, entitled

[[Page 8982]]

``Adenosine derivatives, method of synthesis thereof, and the 
pharmaceutical compositions for the prevention and treatment of the 
inflammatory diseases containing the same as an active ingredient,'' 
filed March 7, 2007, [HHS Ref. No. E-109-2006/0-PCT-01] to Acorn 
Biomedical, Inc., having an office in at 612 SE. 5th Avenue, Suite 
3, Fort Lauderdale, FL 33301 U.S.A. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of adenosine A3 antagonists 
for treatment of glaucoma and intraocular pressure.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
March 29, 2010 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Steven Standley, Ph.D., Licensing and 
Patenting Manager, Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-
3804; Telephone: (301) 435-4074; Facsimile: (301) 402-0220; E-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: Adenosine a3 antagonists applied topically 
to the cornea have been shown to cause a reduction in intraocular 
pressure, which is a means of treating glaucoma.
    The invention relates to several structurally different 
pharmacophores that have been shown to antagonize adenosine a3 
receptors. Molecules are to be tested to optimize for the treatment of 
glaucoma and intraocular pressure in humans.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: February 16, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-3907 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P